The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Achieved record Q1 revenue of $1.4 million, nearly doubling year-over-year performance through increased Catamaran procedure volumes and the first full quarter of Symmetry Plus contribution.

Expanded gross margin by 24 percentage points to 68.5%, driven by improved absorption of fixed production overhead and a more efficient commercial footprint.

Transitioned from a single-approach company to a multi-platform provider, offering physicians optionality across interior, posterior, lateral, and oblique approaches to sacral pelvic anatomy.

Strengthened the competitive moat by securing multiple notices of allowance from the USPTO, bringing the total intellectual property portfolio to 38 granted patents with 31 pending.

Accelerated R&D velocity following the SciVantage asset acquisition, focusing on incremental additions to the Symmetry Plus platform to enhance joint preparation and construct effectiveness.

Established a new training and education center in Tampa, Florida, to address increasing demand and accelerate the conversion of trained physicians into active users.

Management expects structural gross margin gains to persist and further expand toward 70%+ as revenue scales and fixed logistics costs are absorbed.

Full commercial launch of the Symmetry Plus screw technology is underway, transitioning from the alpha phase established in late 2025.

Planned 2026 product roadmap includes the launch of 'Corticator' joint preparation technology followed by an incremental implant addition to the Symmetry Plus construct.

Targeting a regulatory submission and subsequent alpha launch in Q4 2026 for a third surgical approach to the sacral pelvic anatomy, with full commercialization slated for Q1 2027.

Operating expenses are expected to serve as a baseline for the year, with management intending to grow revenue and margins at a faster rate than fixed costs.

Closed a $4.3 million senior convertible note placement in March 2026 to extend the cash runway and fund commercial expansion through the end of the year.

Management acknowledged typical Q1 seasonality headwinds related to insurance deductible resets, though record results suggest strong underlying momentum despite these factors.

Identified hospital Value Analysis Committees (VAC) and facility access approvals as a primary operational complexity and area for targeted commercial investment.

Reported a narrowed net loss of $3.5 million, noting that higher sales and marketing expenses were partially offset by lower stock-based compensation.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management confirmed that while Q1 typically faces 'wild and crazy' December volume followed by deductible resets, the record Q1 results indicate strong adoption momentum.

The company views the strong start as a launchpad for the remainder of 2026 rather than a seasonal peak.

The Symmetry Plus lateral platform is moving from alpha to full launch, with two incremental components (joint preparation and a new implant) arriving later in 2026.

A new third approach technology is expected to enter alpha testing in Q4 2026, adhering to core principles of joint preparation, grafting, and fixation.

Training has evolved from a single-product focus to a comprehensive multi-approach curriculum, supported by the new Tampa facility.

To increase conversion rates, Tenon is leveraging access points gained through the SciVantage acquisition to navigate complex hospital approval (VAC) committees more efficiently.

Management expects margins to remain in the high 60s for the rest of 2026, with a clear path to 70%+ in 2027 as revenue scales.

Expansion will be driven by spreading relatively small fixed production and logistics costs over a larger revenue base.